PT2721062T - Conjugado que compreende oxintomodulina e um fragmento de imunoglobulina e utilização do mesmo - Google Patents

Conjugado que compreende oxintomodulina e um fragmento de imunoglobulina e utilização do mesmo

Info

Publication number: PT2721062T
Authority: PT; Portugal
Prior art keywords: oxyntomodulin; conjugate; immunoglobulin fragment; immunoglobulin; fragment
Prior art date: 2011-06-17

Application number

PT12801247T

Other languages

English (en)

Inventor

Young Choi In

Youb Jung Sung

Chang Kwon Se

Jin Kim Dae

Hee Park Sung

Eun Woo Young

Original Assignee

Hanmi Science Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-17

Filing date

2012-06-15

Publication date

2019-02-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357296&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2721062(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-15 Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd

2019-02-12 Publication of PT2721062T publication Critical patent/PT2721062T/pt

Links

102000008394 Immunoglobulin Fragments Human genes 0.000 title 1
108010021625 Immunoglobulin Fragments Proteins 0.000 title 1
102400000319 Oxyntomodulin Human genes 0.000 title 1
101800001388 Oxyntomodulin Proteins 0.000 title 1
PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

PT12801247T 2011-06-17 2012-06-15 Conjugado que compreende oxintomodulina e um fragmento de imunoglobulina e utilização do mesmo PT2721062T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
KR20110058852		2011-06-17

Publications (1)

Publication Number	Publication Date
PT2721062T true PT2721062T (pt)	2019-02-12

Family

ID=47357296

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT12801247T PT2721062T (pt)	2011-06-17	2012-06-15	Conjugado que compreende oxintomodulina e um fragmento de imunoglobulina e utilização do mesmo

Country Status (32)

Country	Link
US (3)	US9731031B2 (pt)
EP (2)	EP2721062B1 (pt)
JP (2)	JP6038905B2 (pt)
KR (2)	KR101577734B1 (pt)
CN (2)	CN103732616B (pt)
AR (2)	AR086969A1 (pt)
AU (3)	AU2012270366C1 (pt)
BR (1)	BR112013032375B1 (pt)
CA (2)	CA2838504C (pt)
CL (1)	CL2013003619A1 (pt)
CY (1)	CY1121255T1 (pt)
DK (2)	DK2721062T3 (pt)
ES (2)	ES2882520T3 (pt)
HR (1)	HRP20190265T1 (pt)
HU (1)	HUE042585T2 (pt)
IL (4)	IL229759A (pt)
LT (1)	LT2721062T (pt)
MX (1)	MX353402B (pt)
MY (1)	MY164680A (pt)
PE (3)	PE20141178A1 (pt)
PH (1)	PH12018501119A1 (pt)
PL (1)	PL2721062T3 (pt)
PT (1)	PT2721062T (pt)
RS (1)	RS58606B1 (pt)
RU (2)	RU2733544C2 (pt)
SG (2)	SG195275A1 (pt)
SI (1)	SI2721062T1 (pt)
TR (1)	TR201901402T4 (pt)
TW (2)	TWI601744B (pt)
UA (2)	UA114709C2 (pt)
WO (1)	WO2012173422A1 (pt)
ZA (1)	ZA201309013B (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9249407B2 (en)	2006-02-03	2016-02-02	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
US20140113860A1 (en)	2006-02-03	2014-04-24	Prolor Biotech Ltd.	Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en)	2006-02-03	2011-11-01	Modigene, Inc.	Long-acting polypeptides and methods of producing same
US10221228B2 (en)	2006-02-03	2019-03-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en)	2006-02-03	2015-02-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US9663778B2 (en)	2009-07-09	2017-05-30	OPKO Biologies Ltd.	Long-acting coagulation factors and methods of producing same
US10166295B2 (en)	2011-06-02	2019-01-01	Opko Biologics Ltd.	Pegylated OXM variants
ES2968043T3 (es)	2011-06-10	2024-05-06	Hanmi Science Co Ltd	Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de la obesidad que comprende la misma
KR101577734B1 (ko)	2011-06-17	2015-12-29	한미사이언스 주식회사	옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도
KR20130049671A (ko)	2011-11-04	2013-05-14	한미사이언스 주식회사	생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es)	2012-03-08	2014-10-29	Hanmi Science Co Ltd	Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
SG10201702228QA (en)	2012-06-04	2017-04-27	Opko Biolog Ltd	Pegylated oxm variants
KR101968344B1 (ko) *	2012-07-25	2019-04-12	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es)	2012-09-26	2015-05-06	Cadila Healthcare Ltd	Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG11201503370WA (en)	2012-11-06	2015-05-28	Hanmi Pharm Ind Co Ltd	Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) *	2012-11-06	2019-10-01	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
ES2688367T3 (es)	2012-12-21	2018-11-02	Sanofi	Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
AR096891A1 (es) *	2013-07-12	2016-02-03	Hanmi Pharm Ind Co Ltd	Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
AR096890A1 (es) *	2013-07-12	2016-02-03	Hanmi Pharm Ind Co Ltd	Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
US20150158926A1 (en)	2013-10-21	2015-06-11	Opko Biologics, Ltd.	Long-acting polypeptides and methods of producing and administering same
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
MA46146A1 (fr)	2014-01-20	2020-12-31	Hanmi Pharm Ind Co Ltd	Insuline a action prolongée et utilisation associée
SG10202107752PA (en) *	2014-03-31	2021-09-29	Hanmi Pharmaceutical Co Ltd	Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
AR100639A1 (es)	2014-05-29	2016-10-19	Hanmi Pharm Ind Co Ltd	Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) *	2014-05-30	2016-10-26	Hanmi Pharm Ind Co Ltd	Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR20150140177A (ko)	2014-06-05	2015-12-15	한미약품 주식회사	단백질 및 펩타이드의 면역원성을 감소시키는 방법
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh)	2014-09-16	2023-05-11	南韓商韓美藥品股份有限公司	長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
MY185334A (en)	2014-12-30	2021-05-06	Hanmi Pharm Ind Co Ltd	Glucagon derivatives with improved stability
KR102418477B1 (ko)	2014-12-30	2022-07-08	한미약품 주식회사	글루카곤 유도체
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016203482A2 (en)	2015-06-19	2016-12-22	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
BR112017028517A2 (pt)	2015-06-30	2018-08-28	Hanmi Pharm. Co., Ltd.	?composição farmacêutica, vetor, peptídeo, polinucleotídeo e conjugado isolado e composição?
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
UY36870A (es)	2015-08-28	2017-03-31	Hanmi Pharm Ind Co Ltd	Análogos de insulina novedosos
WO2017052329A1 (en) *	2015-09-24	2017-03-30	Hanmi Pharm. Co., Ltd.	Protein complex by use of a specific site of an immunoglobulin fragment for linkage
AU2016382394B2 (en)	2015-12-31	2019-07-04	Hanmi Pharm. Co., Ltd.	Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist
TWI757305B (zh)	2016-06-29	2022-03-11	南韓商韓美藥品股份有限公司	升糖素衍生物、其接合物、及包含其之組成物、及其醫療用途
HUE064463T2 (hu)	2016-07-11	2024-03-28	Opko Biologics Ltd	Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások
JP7158378B2 (ja)	2016-09-23	2022-10-21	ハンミファーマシューティカルカンパニーリミテッド	インスリン受容体との結合力が減少された、インスリンアナログ及びその用途
JOP20190097A1 (ar) *	2016-10-27	2019-04-28	Janssen Pharmaceutica Nv	الجلوبولينات المناعية واستخداماتها
AR110299A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
CN108299553B (zh) *	2017-01-13	2021-07-16	博瑞生物医药（苏州）股份有限公司	胃泌酸调节素修饰物
BR112019016077A2 (pt)	2017-02-03	2020-03-31	Hanmi Pharm. Co., Ltd.	Conjugado da fórmula 1, método para preparar o conjugado, preparação de atuação longa, preparação para prevenir ou tratar diabetes e método para tratar diabetes
US11752216B2 (en)	2017-03-23	2023-09-12	Hanmi Pharm. Co., Ltd.	Insulin analog complex with reduced affinity for insulin receptor and use thereof
SG11202001283PA (en)	2017-08-16	2020-03-30	Dong A St Co Ltd	Acylated oxyntomodulin peptide analog
WO2019035672A1 (ko)	2017-08-16	2019-02-21	동아에스티 주식회사	아실화 옥신토모듈린 펩타이드 유사체
WO2019171352A2 (en) *	2018-03-08	2019-09-12	Janssen Pharmaceutica Nv	Methods of treating severe non-diabetic obesity
TW202015735A (zh)	2018-05-30	2020-05-01	法商賽諾菲公司	包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物
KR20200135618A (ko) *	2019-05-23	2020-12-03	㈜ 디앤디파마텍	폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
EP3823659A4 (en) *	2018-07-19	2022-06-22	D&D Pharmatech Inc.	PHARMACEUTICAL COMPOSITION WITH A POLYPEPTIDE
CN110964116A (zh) *	2018-09-26	2020-04-07	北京辅仁瑞辉生物医药研究院有限公司	GLP1-Fc融合蛋白及其缀合物
WO2020128967A2 (en) *	2018-12-19	2020-06-25	Janssen Pharmaceutica Nv	Methods of treating severe non-diabetic obesity
CN111944055B (zh) *	2019-05-16	2022-08-02	浙江道尔生物科技有限公司	一种治疗代谢疾病的融合蛋白
WO2021235915A1 (ko) *	2020-05-22	2021-11-25	한미약품 주식회사	액상 제제

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en)	1996-03-18	1997-09-25	Board Of Regents, The University Of Texas System	Immunoglobin-like domains with increased half lives
AU749815B2 (en)	1998-03-06	2002-07-04	Chugai Seiyaku Kabushiki Kaisha	Protein-free preparations
US6660843B1 (en) *	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
US6677136B2 (en)	2000-05-03	2004-01-13	Amgen Inc.	Glucagon antagonists
GB0121709D0 (en) *	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
US7217845B2 (en) *	2002-11-25	2007-05-15	Sun Bio, Inc.	Bifunctional polyethylene glycol derivatives
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
US7772188B2 (en) *	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
WO2005035761A1 (en)	2003-10-16	2005-04-21	Compugen Ltd.	Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
KR101135244B1 (ko) *	2007-11-29	2012-04-24	한미사이언스 주식회사	인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US8263084B2 (en)	2003-11-13	2012-09-11	Hanmi Science Co., Ltd	Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
BRPI0406605B8 (pt) *	2003-11-13	2021-05-25	Hanmi Holdings Co Ltd	conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
US20090238838A1 (en)	2003-11-13	2009-09-24	Hanmi Pharm. Ind. Co. Ltd.	Insulinotropic peptide conjugate using an immunoglobulin fc
JP5185624B2 (ja)	2004-12-02	2013-04-17	ドマンティスリミテッド	血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
US20090286723A1 (en)	2005-02-11	2009-11-19	Amylin Pharmaceuticals, Inc.	Hybrid Polypeptides with Selectable Properties
CA2597649A1 (en)	2005-02-11	2006-08-17	Amylin Pharmaceuticals, Inc.	Gip analog and hybrid polypeptides with selectable properties
JP5114381B2 (ja) *	2005-03-31	2013-01-09	アミリン・ファーマシューティカルズ，インコーポレイテッド	精神疾患および障害治療用アミリンおよびアミリンアゴニスト
KR100754667B1 (ko)	2005-04-08	2007-09-03	한미약품 주식회사	비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
GB0511986D0 (en)	2005-06-13	2005-07-20	Imp College Innovations Ltd	Novel compounds and their effects on feeding behaviour
AU2006258841B2 (en)	2005-06-13	2012-05-03	Imperial Innovations Limited	Oxyntomodulin analogues and their effects on feeding behaviour
WO2007030375A2 (en)	2005-09-08	2007-03-15	Children's Hospital Medical Center	Lysosomal acid lipase therapy for nafld and related diseases
EP2471810A1 (en) *	2006-02-22	2012-07-04	Merck Sharp & Dohme Corporation	Oxyntomodulin derivatives
AU2007258609B2 (en)	2006-06-07	2013-01-24	Human Genome Sciences, Inc.	Albumin fusion proteins
KR100880509B1 (ko)	2006-10-16	2009-01-28	한미약품 주식회사	재조합 단백질의 대량 생산을 위한 신규한 벡터, 발현세포주 및 이를 이용한 재조합 단백질의 생산 방법
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
GB0624868D0 (en) *	2006-12-13	2007-01-24	Imp Innovations Ltd	Novel compounds and their effects on feeding behaviour
JP2008169195A (ja)	2007-01-05	2008-07-24	Hanmi Pharmaceutical Co Ltd	キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20090098130A1 (en)	2007-01-05	2009-04-16	Bradshaw Curt W	Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US8454971B2 (en) *	2007-02-15	2013-06-04	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
WO2009009562A2 (en)	2007-07-10	2009-01-15	Eli Lilly And Company	Glp-1-fc fusion protein formulation
JP5345617B2 (ja)	2007-07-27	2013-11-20	バイエル・クロップサイエンス・アーゲー	三元活性化合物組合せ
CA2699065A1 (en)	2007-09-11	2009-04-02	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
JP5771005B2 (ja)	2007-10-30	2015-08-26	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物
CN101983066B (zh)	2008-01-30	2016-06-29	印第安那大学科技研究公司	基于酯的胰岛素前药
JP5753779B2 (ja)	2008-06-17	2015-07-22	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
US8546327B2 (en)	2008-06-17	2013-10-01	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
WO2010013012A2 (en)	2008-08-01	2010-02-04	Lund University Bioscience Ab	Novel polypeptides and uses thereof
WO2010033220A2 (en)	2008-09-19	2010-03-25	Nektar Therapeutics	Modified therapeutics peptides, methods of their preparation and use
WO2010033240A2 (en)	2008-09-19	2010-03-25	Nektar Therapeutics	Carbohydrate-based drug delivery polymers and conjugates thereof
CN102282166B (zh)	2008-12-15	2015-04-01	西兰制药公司	胰高血糖素类似物
KR20110110174A (ko) *	2008-12-19	2011-10-06	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
CN102348715B (zh)	2009-02-03	2017-12-08	阿穆尼克斯运营公司	延伸重组多肽和包含该延伸重组多肽的组合物
WO2010096052A1 (en)	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs
KR101164453B1 (ko)	2009-03-20	2012-07-11	한미사이언스 주식회사	위치특이적 생리활성 폴리펩타이드 결합체의 제조방법
US8734796B2 (en)	2009-03-20	2014-05-27	Amgen Inc.	Carrier immunoglobulins
MX2011013625A (es)	2009-06-16	2012-01-20	Univ Indiana Res & Tech Corp	Compuestos glucagon activo de receptor de gip.
SG177609A1 (en)	2009-07-13	2012-02-28	Zealand Pharma As	Acylated glucagon analogues
US20120294855A1 (en)	2009-11-03	2012-11-22	Eli Lilly & Company	Glp-1 receptor agonist compounds for obstructive sleep apnea
WO2011071957A1 (en)	2009-12-07	2011-06-16	Sea Lane Biotechnologies, Llc	Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
WO2011075393A2 (en)	2009-12-18	2011-06-23	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
AR079344A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
AR079345A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina
RU2559320C2 (ru)	2010-03-26	2015-08-10	Ново Нордиск А/С	Новые аналоги глюкагона
KR20130111923A (ko)	2010-05-13	2013-10-11	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
CA2796894A1 (en)	2010-06-24	2011-12-29	Indiana University Research And Technology Corporation	Amide based glucagon superfamily peptide prodrugs
KR101337797B1 (ko)	2010-07-14	2013-12-06	한미사이언스 주식회사	지속형 인간 성장 호르몬 결합체 액상 제제
KR101382593B1 (ko)	2010-07-21	2014-04-10	한미사이언스 주식회사	신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
WO2012032567A1 (ja)	2010-09-06	2012-03-15	パナソニック株式会社	表示装置及びその制御方法
CN101974077A (zh)	2010-09-15	2011-02-16	南京瑞年天平医药科技有限公司	一种新颖的多肽化合物
KR101303388B1 (ko)	2010-10-26	2013-09-03	한미사이언스 주식회사	지속형 인터페론 알파 결합체의 액상 제제
KR101767570B1 (ko)	2010-10-26	2017-08-14	한미사이언스 주식회사	항 비만 펩타이드의 지속형 결합체
CN102010473A (zh)	2010-11-10	2011-04-13	曹鹏	重组胃泌酸调节素融合蛋白及其制备和应用
AR084558A1 (es)	2010-12-22	2013-05-22	Marcadia Biotech	Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
JP6118500B2 (ja)	2011-02-28	2017-04-19	ロームアンドハースエレクトロニックマテリアルズエルエルシーＲｏｈｍａｎｄＨａａｓＥｌｅｃｔｒｏｎｉｃＭａｔｅｒｉａｌｓＬＬＣ	フォトレジスト組成物、およびフォトリソグラフィパターンを形成する方法
KR101161526B1 (ko)	2011-05-16	2012-07-02	숭실대학교산학협력단	연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법
ES2968043T3 (es)	2011-06-10	2024-05-06	Hanmi Science Co Ltd	Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de la obesidad que comprende la misma
KR101577734B1 (ko)	2011-06-17	2015-12-29	한미사이언스 주식회사	옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도
CN103748109A (zh)	2011-06-22	2014-04-23	印第安纳大学研究及科技有限公司	胰高血糖素/glp-1受体共同激动剂
KR101665009B1 (ko)	2012-03-09	2016-10-11	한미사이언스 주식회사	비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
CN104487082A (zh)	2012-04-19	2015-04-01	奥普科生物制品有限公司	长效胃泌酸调节素变体及其生产方法
RU2015101697A (ru)	2012-06-21	2016-08-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	Аналоги глюкагона, обладающие активностью рецептора gip
KR101373563B1 (ko)	2012-07-25	2014-03-12	전북대학교산학협력단	Ｔｏｆ-ｍｒａ를 이용한 혈류특성 및 ｍｒ-신호강도구배(전단율) 유도방법
KR101968344B1 (ko)	2012-07-25	2019-04-12	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR092873A1 (es)	2012-09-26	2015-05-06	Cadila Healthcare Ltd	Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko)	2012-11-06	2019-10-01	한미약품 주식회사	옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
SG11201503370WA (en)	2012-11-06	2015-05-28	Hanmi Pharm Ind Co Ltd	Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
JP6137046B2 (ja)	2014-05-09	2017-05-31	信越化学工業株式会社	単量体、高分子化合物、レジスト材料及びパターン形成方法
TWI802396B (zh)	2014-09-16	2023-05-11	南韓商韓美藥品股份有限公司	長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
WO2019171352A2 (en)	2018-03-08	2019-09-12	Janssen Pharmaceutica Nv	Methods of treating severe non-diabetic obesity

2012
- 2012-06-15 KR KR1020120064110A patent/KR101577734B1/ko active IP Right Grant
- 2012-06-15 JP JP2014515759A patent/JP6038905B2/ja active Active
- 2012-06-15 ES ES18205668T patent/ES2882520T3/es active Active
- 2012-06-15 SG SG2013089370A patent/SG195275A1/en unknown
- 2012-06-15 BR BR112013032375-2A patent/BR112013032375B1/pt active IP Right Grant
- 2012-06-15 DK DK12801247.3T patent/DK2721062T3/en active
- 2012-06-15 CA CA2838504A patent/CA2838504C/en active Active
- 2012-06-15 WO PCT/KR2012/004722 patent/WO2012173422A1/en active Application Filing
- 2012-06-15 EP EP12801247.3A patent/EP2721062B1/en active Active
- 2012-06-15 HU HUE12801247A patent/HUE042585T2/hu unknown
- 2012-06-15 MY MYPI2013004311A patent/MY164680A/en unknown
- 2012-06-15 MX MX2013014779A patent/MX353402B/es active IP Right Grant
- 2012-06-15 PE PE2013002814A patent/PE20141178A1/es active IP Right Grant
- 2012-06-15 TW TW103138318A patent/TWI601744B/zh active
- 2012-06-15 UA UAA201314024A patent/UA114709C2/uk unknown
- 2012-06-15 PT PT12801247T patent/PT2721062T/pt unknown
- 2012-06-15 TR TR2019/01402T patent/TR201901402T4/tr unknown
- 2012-06-15 CA CA3080189A patent/CA3080189C/en active Active
- 2012-06-15 RS RS20190079A patent/RS58606B1/sr unknown
- 2012-06-15 UA UAA201702255A patent/UA125895C2/uk unknown
- 2012-06-15 EP EP18205668.9A patent/EP3502129B1/en active Active
- 2012-06-15 PH PH12018501119A patent/PH12018501119A1/en unknown
- 2012-06-15 PE PE2018000578A patent/PE20181268A1/es unknown
- 2012-06-15 RU RU2016147505A patent/RU2733544C2/ru active
- 2012-06-15 AR ARP120102154A patent/AR086969A1/es active IP Right Grant
- 2012-06-15 SG SG10201605006XA patent/SG10201605006XA/en unknown
- 2012-06-15 PE PE2022000590A patent/PE20230404A1/es unknown
- 2012-06-15 AU AU2012270366A patent/AU2012270366C1/en active Active
- 2012-06-15 DK DK18205668.9T patent/DK3502129T3/da active
- 2012-06-15 TW TW101121483A patent/TWI519541B/zh not_active IP Right Cessation
- 2012-06-15 LT LTEP12801247.3T patent/LT2721062T/lt unknown
- 2012-06-15 US US14/126,914 patent/US9731031B2/en active Active
- 2012-06-15 PL PL12801247T patent/PL2721062T3/pl unknown
- 2012-06-15 RU RU2013153198A patent/RU2607365C2/ru active
- 2012-06-15 CN CN201280039781.4A patent/CN103732616B/zh active Active
- 2012-06-15 ES ES12801247T patent/ES2710356T3/es active Active
- 2012-06-15 CN CN201810801214.7A patent/CN109306015B/zh active Active
- 2012-06-15 SI SI201231525T patent/SI2721062T1/sl unknown
2013
- 2013-12-02 ZA ZA2013/09013A patent/ZA201309013B/en unknown
- 2013-12-02 IL IL229759A patent/IL229759A/en active IP Right Grant
- 2013-12-17 CL CL2013003619A patent/CL2013003619A1/es unknown
2014
- 2014-10-22 KR KR1020140143521A patent/KR101591411B1/ko active IP Right Grant
2016
- 2016-05-09 IL IL245556A patent/IL245556B/en active IP Right Grant
- 2016-11-01 JP JP2016214019A patent/JP6345216B2/ja active Active
2017
- 2017-04-21 AU AU2017202672A patent/AU2017202672B2/en active Active
- 2017-06-28 US US15/636,160 patent/US10363320B2/en active Active
2018
- 2018-03-06 IL IL257928A patent/IL257928B/en active IP Right Grant
- 2018-12-18 AU AU2018282298A patent/AU2018282298B2/en active Active
2019
- 2019-02-11 HR HRP20190265TT patent/HRP20190265T1/hr unknown
- 2019-02-12 CY CY20191100181T patent/CY1121255T1/el unknown
- 2019-07-09 US US16/506,717 patent/US11872283B2/en active Active
2020
- 2020-01-29 IL IL272345A patent/IL272345B/en active IP Right Grant
2022
- 2022-05-19 AR ARP220101329A patent/AR125914A2/es unknown

Also Published As

Publication number	Publication date
PL2721062T3 (pl)	2019-05-31
NZ618811A (en)	2016-05-27
CN103732616A (zh)	2014-04-16
JP2014518209A (ja)	2014-07-28
ES2882520T3 (es)	2021-12-02
RU2733544C2 (ru)	2020-10-05
NZ733478A (en)	2020-06-26
AU2017202672B2 (en)	2019-01-17
PE20141178A1 (es)	2014-09-12
CL2013003619A1 (es)	2014-05-30
US9731031B2 (en)	2017-08-15
SG10201605006XA (en)	2016-08-30
IL257928A (en)	2018-06-28
US20140212440A1 (en)	2014-07-31
UA125895C2 (uk)	2022-07-06
ES2710356T3 (es)	2019-04-24
US11872283B2 (en)	2024-01-16
AU2012270366C1 (en)	2017-07-13
IL257928B (en)	2020-02-27
IL245556B (en)	2018-03-29
WO2012173422A9 (en)	2013-03-14
KR20140133493A (ko)	2014-11-19
DK2721062T3 (en)	2019-02-25
EP3502129A1 (en)	2019-06-26
US20170340753A1 (en)	2017-11-30
IL229759A (en)	2017-08-31
KR101591411B1 (ko)	2016-02-05
TR201901402T4 (tr)	2019-02-21
US10363320B2 (en)	2019-07-30
AU2012270366A1 (en)	2014-01-16
KR20120139579A (ko)	2012-12-27
BR112013032375A2 (pt)	2016-11-22
TWI519541B (zh)	2016-02-01
CA3080189C (en)	2023-01-17
UA114709C2 (uk)	2017-07-25
TW201305195A (zh)	2013-02-01
SG195275A1 (en)	2013-12-30
CY1121255T1 (el)	2020-05-29
CN109306015A (zh)	2019-02-05
CA2838504C (en)	2020-07-21
AU2018282298A1 (en)	2019-01-17
AU2018282298B2 (en)	2020-06-18
IL229759A0 (en)	2014-01-30
JP2017071609A (ja)	2017-04-13
AU2012270366B2 (en)	2017-02-02
RU2016147505A3 (pt)	2020-04-08
TW201506037A (zh)	2015-02-16
EP2721062A1 (en)	2014-04-23
CA3080189A1 (en)	2012-12-20
PH12018501119A1 (en)	2019-02-04
MX2013014779A (es)	2014-06-23
DK3502129T3 (da)	2021-07-12
IL245556A0 (en)	2016-06-30
ZA201309013B (en)	2014-11-26
EP2721062A4 (en)	2014-11-12
JP6038905B2 (ja)	2016-12-07
HUE042585T2 (hu)	2019-07-29
RU2013153198A (ru)	2015-07-27
JP6345216B2 (ja)	2018-06-20
PE20230404A1 (es)	2023-03-07
RU2016147505A (ru)	2018-10-24
IL272345B (en)	2021-01-31
NZ742400A (en)	2021-05-28
EP2721062B1 (en)	2018-11-14
CN109306015B (zh)	2022-04-26
TWI601744B (zh)	2017-10-11
HRP20190265T1 (hr)	2019-04-05
MX353402B (es)	2018-01-11
MY164680A (en)	2018-01-30
AR086969A1 (es)	2014-02-05
NZ718999A (en)	2017-07-28
AR125914A2 (es)	2023-08-23
AU2017202672A1 (en)	2017-05-11
BR112013032375B1 (pt)	2022-09-20
KR101577734B1 (ko)	2015-12-29
US20190321485A1 (en)	2019-10-24
WO2012173422A1 (en)	2012-12-20
CN103732616B (zh)	2018-08-17
EP3502129B1 (en)	2021-04-07
PE20181268A1 (es)	2018-08-03
IL272345A (en)	2020-03-31
CA2838504A1 (en)	2012-12-20
RS58606B1 (sr)	2019-05-31
LT2721062T (lt)	2019-02-11
RU2607365C2 (ru)	2017-01-10
SI2721062T1 (sl)	2019-03-29

Publication	Publication Date	Title
HRP20190265T1 (hr)	2019-04-05	Konjugat koji sadrži oksintomodulin i fragment imunoglobulina i njegova uporaba
HK1245290A1 (zh)	2018-08-24	使用免疫球蛋白片段的胰島素綴合物
HK1194757A1 (zh)	2014-10-24	供人類使用的抗體、可變區與鏈特製
GB201115529D0 (en)	2011-10-26	Antibodies, uses and methods
GB201115280D0 (en)	2011-10-19	Antibodies, uses and methods
PL2536370T3 (pl)	2015-06-30	Opaskowa orteza kompresyjna
EP2721071A4 (en)	2015-01-21	TEM8 ANTIBODIES, CONJUGATES THEREOF AND THEIR USE
IL222930A0 (en)	2012-12-31	Chlorotoxin variants, conjugates and methods for their use
EP2797621A4 (en)	2015-09-02	LPG-2 CONJUGATE TO A SPECIFIC SITE USING AN IMMUNOGLOBULIN FRAGMENT
EP2733406A4 (en)	2015-03-18	ROOF COVERS, PIPING AND VEHICLE
EP2752419A4 (en)	2015-04-29	SPIROBENZYLAMINE-PHOSPHINE, ITS PREPARATION METHOD AND USE
EP2685588A4 (en)	2014-08-06	CHARGER ON BOARD, AND ITS PROGRAM
EP2744828A4 (en)	2014-12-31	JAML-SPECIFIC BINDING AGENTS, ANTIBODIES AND USES THEREOF
HK1191942A1 (zh)	2014-08-08	新型六氫環戊二烯並吡咯酮，六氫吡咯並吡咯酮，八氫吡咯並吡啶酮和八氫吡啶酮化合物
EP2785738A4 (en)	2015-07-22	ANTI-NPY ANTI-PYY ANTIBODIES AND USES THEREOF
PL2566419T3 (pl)	2019-07-31	Orteza
GB201004270D0 (en)	2010-04-28	Stinger deploymen device
EP2580192A4 (en)	2013-12-11	METHODS OF MAKING METABOLITES OF TETRANOR-PROSTAGLANDIN D, J, E, A AND F
AU4935P (en)	2014-10-21	FerrupenGL Pimelea ferruginea